Should I buy or sell Vericel stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VCEL shares. View VCEL analyst ratings or view top-rated stocks .

What is Vericel's stock price target for 2024?

6 brokerages have issued twelve-month target prices for Vericel's shares. Their VCEL share price targets range from $39.00 to $54.00. On average, they anticipate the company's share price to reach $46.40 in the next year. This suggests a possible upside of 5.8% from the stock's current price. View analysts price targets for VCEL or view top-rated stocks among Wall Street analysts .

How have VCEL shares performed in 2024?

Vericel's stock was trading at $35.61 on January 1st, 2024. Since then, VCEL shares have increased by 23.2% and is now trading at $43.86. View the best growth stocks for 2024 here .

Are investors shorting Vericel?

Vericel saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 4,390,000 shares, an increase of 85.2% from the March 15th total of 2,370,000 shares. Based on an average daily volume of 536,800 shares, the days-to-cover ratio is presently 8.2 days. View Vericel's Short Interest .

When is Vericel's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our VCEL earnings forecast .

How were Vericel's earnings last quarter?

Vericel Co. (NASDAQ:VCEL) issued its quarterly earnings results on Thursday, February, 29th. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.18 by $0.08. The biotechnology company had revenue of $65 million for the quarter, compared to the consensus estimate of $64.28 million. Vericel had a negative trailing twelve-month return on equity of 1.55% and a negative net margin of 1.61%. The company's revenue for the quarter was up 23.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.12 earnings per share.

What ETFs hold Vericel's stock?

ETFs with the largest weight of Vericel (NASDAQ:VCEL) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE) , Invesco S&P SmallCap Health Care ETF (PSCH) , WisdomTree BioRevolution Fund (WDNA) , ALPS Medical Breakthroughs ETF (SBIO) , Invesco Dorsey Wright Healthcare Momentum ETF (PTH) , SPDR S&P Biotech ETF (XBI) , Invesco S&P SmallCap 600 Pure Growth ETF (RZG) and Syntax Stratified SmallCap ETF (SSLY) .

What guidance has Vericel issued on next quarter's earnings?

Vericel issued an update on its FY 2024 earnings guidance on Thursday, February, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $237.0 million-$241.0 million, compared to the consensus revenue estimate of $240.8 million.

What is Nick Colangelo's approval rating as Vericel's CEO?

6 employees have rated Vericel Chief Executive Officer Nick Colangelo on Glassdoor.com . Nick Colangelo has an approval rating of 49% among the company's employees. This puts Nick Colangelo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Vericel own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL) , Novavax (NVAX) , Hello Group (MOMO) , Dynavax Technologies (DVAX) , Synergy Pharmaceuticals (SGYP) , Sorrento Therapeutics (SRNE) , TG Therapeutics (TGTX) , Verastem (VSTM) , Amarin (AMRN) and NVIDIA (NVDA) .

Who are Vericel's major shareholders?

Vericel's stock is owned by a variety of retail and institutional investors. Top institutional investors include Congress Asset Management Co. MA (1.73%), Allspring Global Investments Holdings LLC (0.82%), Congress Wealth Management LLC DE (0.22%), Los Angeles Capital Management LLC (0.06%), Park Avenue Securities LLC (0.01%) and Juncture Wealth Strategies LLC (0.01%). Insiders that own company stock include Dominick Colangelo, Jonathan Mark Hopper , Jonathan Siegal, Michael Halpin , Paul K Wotton , Robert L Md Zerbe, Sean C Flynn and Steven C Gilman . View institutional ownership trends .

How do I buy shares of Vericel?

Shares of VCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:VCEL

Vericel (VCEL) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free VCEL Stock Alerts

$43.86

-2.40 (-5.19%)

(As of 04/18/2024 ET)

Compare

Today's Range: $43.69
▼
$46.56
50-Day Range: $43.86
▼
$52.90
52-Week Range: $29.24
▼
$53.05

Volume: 426,930 shs
Average Volume: 555,399 shs
Market Capitalization: $2.12 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $46.40

Get Vericel alerts:

Vericel MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 5.8% Upside
$46.40 Price Target
Short Interest: Bearish
9.07% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 1.02
Based on 4 Articles This Week
Insider Trading: Selling Shares
$2.76 M Sold Last Quarter
Proj. Earnings Growth: 455.56%
From $0.09 to $0.50 Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.58 out of 5 stars

Medical Sector

864th out of 918 stocks

Biological Products, Except Diagnostic Industry

142nd out of 147 stocks

1.5

Analyst's Opinion

Consensus Rating
Vericel has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Vericel has only been the subject of 2 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
9.07% of the outstanding shares of Vericel have been sold short.
Short Interest Ratio / Days to Cover
Vericel has a short interest ratio ("days to cover") of 8.2.
Change versus previous month
Short interest in Vericel has recently increased by 85.23%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Vericel does not currently pay a dividend.
Dividend Growth
Vericel does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for VCEL.

2.8

News and Social Media Coverage

News Sentiment
Vericel has a news sentiment score of 1.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Vericel this week, compared to 3 articles on an average week.
Search Interest
Only 1 people have searched for VCEL on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Vericel to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vericel insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,761,270.00 in company stock.
Percentage Held by Insiders
Only 5.20% of the stock of Vericel is held by insiders.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Vericel are expected to grow by 455.56% in the coming year, from $0.09 to $0.50 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Vericel is -487.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Vericel is -487.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Vericel has a P/B Ratio of 9.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Vericel Stock (NASDAQ:VCEL)

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

VCEL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

VCEL Stock News Headlines

March 30, 2024 | insidertrades.com

Vericel Co. (NASDAQ:VCEL) Director Robert L. Md Zerbe Sells 3,278 Shares

April 17, 2024 | money.usnews.com

Vericel Corp

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

April 13, 2024 | finance.yahoo.com

Vericel Corporation (NASDAQ:VCEL) On The Verge Of Breaking Even

April 8, 2024 | americanbankingnews.com

Vericel Co. (NASDAQ:VCEL) Receives Consensus Rating of "Buy" from Brokerages

April 7, 2024 | nasdaq.com

Commit To Buy Vericel At $25, Earn 9% Annualized Using Options

March 27, 2024 | markets.businessinsider.com

Analyst Scoreboard: 5 Ratings For Vericel

March 3, 2024 | ca.finance.yahoo.com

VCEL Oct 2024 50.000 call

April 18, 2024 | DTI (Ad)

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

March 3, 2024 | finance.yahoo.com

US$52.07 - That's What Analysts Think Vericel Corporation (NASDAQ:VCEL) Is Worth After These Results

March 2, 2024 | seekingalpha.com

Vericel Corporation (VCEL) Q4 2023 Earnings Call Transcript

March 2, 2024 | finance.yahoo.com

Vericel Full Year 2023 Earnings: EPS Beats Expectations

March 1, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Vericel on Strong Financials and Growth Prospects

March 1, 2024 | markets.businessinsider.com

A Closer Look at 4 Analyst Recommendations For Vericel

March 1, 2024 | finance.yahoo.com

Vericel Corporation (NASDAQ:VCEL) Q4 2023 Earnings Call Transcript

March 1, 2024 | finance.yahoo.com

Vericel Corporation (NASDAQ:VCEL) Shares Could Be 48% Below Their Intrinsic Value Estimate

February 29, 2024 | finanznachrichten.de

Vericel Corporation: Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance

February 29, 2024 | msn.com

Vericel GAAP EPS of $0.26 beats by $0.09, revenue of $65M beats by $1.05M

February 29, 2024 | finance.yahoo.com

Vericel Corp (VCEL) Reports Robust Revenue and EBITDA Growth in Q4 and Full-Year 2023

February 29, 2024 | seekingalpha.com

Vericel Corporation 2023 Q4 - Results - Earnings Call Presentation

February 29, 2024 | globenewswire.com

Vericel Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Full-Year 2024 Financial Guidance

February 27, 2024 | globenewswire.com

Vericel to Present at the TD Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024

February 26, 2024 | investorplace.com

3 Top Pharma Stocks for Investors Betting on a Biotech Boom

February 23, 2024 | finance.yahoo.com

Vericel Corporation (VCEL)

February 21, 2024 | finance.yahoo.com

CRSP Mar 2024 79.000 put

February 18, 2024 | ca.finance.yahoo.com

CRSP Mar 2024 72.000 put

February 18, 2024 | finance.yahoo.com

Vericel Corp President and CEO Dominick Colangelo Sells 35,000 Shares

See More Headlines

Receive VCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vericel and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/29/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Current Symbol: NASDAQ:VCEL
CUSIP: N/A
CIK: 887359
Web: www.vcel.com
Phone: (617) 588-5555
Fax: 617-588-5554
Employees: 314
Year Founded: 1989

Price Target and Rating

Average Stock Price Target: $46.40
High Stock Price Target: $54.00
Low Stock Price Target: $39.00
Potential Upside/Downside: +5.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.09)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 487.33
P/E Growth: N/A
Net Income: $-3,180,000.00
Net Margins: -1.61%
Pretax Margin: -1.20%
Return on Equity: -1.55%
Return on Assets: -1.02%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.49
Quick Ratio: 4.21

Sales & Book Value

Annual Sales: $197.52 million
Price / Sales: 10.74
Cash Flow: $0.02 per share
Price / Cash Flow: 2,696.64
Book Value: $4.73 per share
Price / Book: 9.27

Miscellaneous

Outstanding Shares: 48,380,000
Free Float: 45,864,000
Market Cap: $2.12 billion
Optionable: Optionable
Beta: 1.71

Social Links

10 Best Stocks to Own in 2024

Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio.

Get This Free Report

Key Executives

Mr. Dominick C. Colangelo Esq. (Age 60)
CEO, President & Director
Comp: $1.54M
Mr. Joseph Anthony Mara Jr. (Age 48)
CFO & Treasurer
Comp: $750.61k
Mr. Michael Halpin (Age 63)
Chief Operating Officer
Comp: $796.91k
Mr. Sean C. Flynn (Age 50)
Senior VP, General Counsel & Secretary
Comp: $657.01k
Dr. Jonathan M. Hopper FRCSEd. (Age 62)
M.B. Ch.B., Chief Medical Officer
Comp: $672.16k
Mr. Jonathan D. Siegal
Principal Accounting Officer, VP & Corporate Controller
Mr. Eric Burns
Vice President of Finance & Investor Relations
Mr. Patrick J. Fowler
Senior Vice President of Corporate Development & Strategy
Mr. Patrick Helfrich
Vice President of Marketing & Commercial Strategy
Ms. Heidi Hassen
Senior Vice President of Human Resources

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VCEL Stock Analysis - Frequently Asked Questions

Should I buy or sell Vericel stock right now?: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VCEL shares.
View VCEL analyst ratings or view top-rated stocks.
What is Vericel's stock price target for 2024?: 6 brokerages have issued twelve-month target prices for Vericel's shares. Their VCEL share price targets range from $39.00 to $54.00. On average, they anticipate the company's share price to reach $46.40 in the next year. This suggests a possible upside of 5.8% from the stock's current price.
View analysts price targets for VCEL or view top-rated stocks among Wall Street analysts.
How have VCEL shares performed in 2024?: Vericel's stock was trading at $35.61 on January 1st, 2024. Since then, VCEL shares have increased by 23.2% and is now trading at $43.86.
View the best growth stocks for 2024 here.
Are investors shorting Vericel?: Vericel saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 4,390,000 shares, an increase of 85.2% from the March 15th total of 2,370,000 shares. Based on an average daily volume of 536,800 shares, the days-to-cover ratio is presently 8.2 days.
View Vericel's Short Interest.
When is Vericel's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our VCEL earnings forecast.
How were Vericel's earnings last quarter?: Vericel Co. (NASDAQ:VCEL) issued its quarterly earnings results on Thursday, February, 29th. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.18 by $0.08. The biotechnology company had revenue of $65 million for the quarter, compared to the consensus estimate of $64.28 million. Vericel had a negative trailing twelve-month return on equity of 1.55% and a negative net margin of 1.61%. The company's revenue for the quarter was up 23.3% compared to the same quarter last year. During the same quarter last year, the firm earned $0.12 earnings per share.

What ETFs hold Vericel's stock?: ETFs with the largest weight of Vericel (NASDAQ:VCEL) stock in their portfolio include Invesco Biotechnology & Genome ETF (PBE), Invesco S&P SmallCap Health Care ETF (PSCH), WisdomTree BioRevolution Fund (WDNA), ALPS Medical Breakthroughs ETF (SBIO), Invesco Dorsey Wright Healthcare Momentum ETF (PTH), SPDR S&P Biotech ETF (XBI), Invesco S&P SmallCap 600 Pure Growth ETF (RZG) and Syntax Stratified SmallCap ETF (SSLY).
What guidance has Vericel issued on next quarter's earnings?: Vericel issued an update on its FY 2024 earnings guidance on Thursday, February, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $237.0 million-$241.0 million, compared to the consensus revenue estimate of $240.8 million.
What is Nick Colangelo's approval rating as Vericel's CEO?: 6 employees have rated Vericel Chief Executive Officer Nick Colangelo on Glassdoor.com. Nick Colangelo has an approval rating of 49% among the company's employees. This puts Nick Colangelo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Vericel own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Novavax (NVAX), Hello Group (MOMO), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Verastem (VSTM), Amarin (AMRN) and NVIDIA (NVDA).
Who are Vericel's major shareholders?: Vericel's stock is owned by a variety of retail and institutional investors. Top institutional investors include Congress Asset Management Co. MA (1.73%), Allspring Global Investments Holdings LLC (0.82%), Congress Wealth Management LLC DE (0.22%), Los Angeles Capital Management LLC (0.06%), Park Avenue Securities LLC (0.01%) and Juncture Wealth Strategies LLC (0.01%). Insiders that own company stock include Dominick Colangelo, Jonathan Mark Hopper, Jonathan Siegal, Michael Halpin, Paul K Wotton, Robert L Md Zerbe, Sean C Flynn and Steven C Gilman.
View institutional ownership trends.
How do I buy shares of Vericel?: Shares of VCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VCEL) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Vericel (VCEL) Stock Price, News & Analysis

Vericel MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Vericel Stock (NASDAQ:VCEL)

VCEL Stock Price History

VCEL Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

VCEL Stock Analysis - Frequently Asked Questions

Overall MarketRank^™